Core Insights - The article highlights the dual approach of global and local innovation showcased at the 8th China International Import Expo, particularly through the lens of Fosun Pharma's exhibition [1][2] - Fosun Pharma's products, such as the Marie upright particle therapy system, are designed to meet local clinical needs while also contributing to global research and development [1] Group 1: Local Innovation Impact - Fosun Pharma's CAR-T product, Yikaida, has treated over 1,000 lymphoma patients across 190 treatment centers in 29 provinces, demonstrating the local practice's role in enhancing global accessibility of CAR-T therapies [2] - The Marie upright particle therapy system is a significant innovation that reduces the treatment room size from 120 square meters to 30 square meters, making it more adaptable to existing hospital spaces [1] Group 2: Global Collaboration and Development - The Da Vinci surgical robot has evolved from being merely imported equipment to creating a surgical robot ecosystem in China, reflecting a high-quality development phase for the domestic surgical robot industry [2] - Over 15,000 medical professionals have been trained in the use of the Da Vinci robot, with their experiences feeding back into global technological upgrades [2] Group 3: Future Directions - Fosun Pharma aims to promote the local implementation of innovative technologies to provide better treatment options for cancer patients in China [1] - The company emphasizes that open collaboration is essential for accelerating innovation, positioning China as a significant opportunity for global development [2]

Core Insights - The China International Import Expo (CIIE) has seen consistent participation from 170 overseas companies and 27 institutions over its eight-year history, showcasing the growing commitment of international firms to the Chinese market [1] - The expo serves as an effective platform for transforming exhibits into commercial products, enhancing investment confidence and fostering innovation [2][3] Group 1: Company Participation and Growth - Amorepacific showcased nearly 300 products, including over 20 new launches exclusive to China, indicating a strong commitment to the Chinese market [2] - Lesaffre has experienced significant growth in investment and business performance in China, leveraging the expo's platform for rapid development [2] - Hansgrohe expanded its exhibition space from 36 square meters in 2018 to 180 square meters in 2025, highlighting its growth trajectory in the Chinese market [2] Group 2: Innovation and Development - Emerson has established 15 manufacturing bases and 8 R&D centers in China, emphasizing its commitment to local needs and global support [3] - Fosun Pharma has focused on open innovation, showcasing advancements in medical technology and committing to further innovation in China [3] - Toyota and Pony.ai introduced a mass-production version of their autonomous vehicle at the expo, set to launch in major Chinese cities next year [3] Group 3: Market Opportunities and Global Sharing - The CIIE acts as a bridge for foreign companies entering the Chinese market while facilitating the export of Chinese goods [4] - L'Oréal has consistently participated in the expo, demonstrating confidence in the Chinese market through new products and collaborations [4] - Charoen Pokphand Group presented 231 products, including new Thai offerings, while also supporting the export of Chinese goods [5]

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on December 2 at 13:30 [2][3] - The meeting will be conducted using a combination of on-site and online voting methods [3][4] - A-share shareholders can vote through the Shanghai Stock Exchange's online voting system during specified trading hours on the meeting day [4][8] Group 2 - The meeting will take place at the Shanghai Tianxi Jiafu Putike Hotel, located at 358 Hongxu Road, Shanghai [3] - A-share shareholders must register for the meeting either online or on-site, with specific requirements for both individual and institutional shareholders [15][17] - H-share shareholders are advised to refer to the company's announcement on the Hong Kong Stock Exchange for registration details [12][19] Group 3 - The company announced a pledge and release of shares by its controlling shareholder, Fosun High Technology, with a total of 961,424,455 shares held as of November 6, 2025, accounting for 36.00% of the total shares [27][28] - After the pledge and release, the remaining pledged shares amount to 546,925,000 shares, representing 20.48% of the total shares [27][30] - The controlling shareholder confirmed that the pledged shares are not used for major asset restructuring or performance compensation guarantees [29][32]

Group 1 - The announcement details the pledge and release of shares by the controlling shareholder, Fosun High Technology, which holds approximately 36.00% of the company's total shares as of November 6, 2025 [2][3] - After the pledge and release, the remaining pledged shares by Fosun High Technology amount to 546,925,000 shares, representing about 20.48% of the total shares [2][3] - The total shares held by Fosun High Technology and its concerted parties amount to 967,812,180 shares, which is approximately 36.24% of the company's total shares [2][3] Group 2 - As of November 6, 2025, 36,670,000 pledged shares are expected to mature within the next year, accounting for about 13.73% of the company's total shares, with a corresponding financing balance of RMB 3.431 billion [7] - Fosun High Technology confirms that its operations are normal and it has the ability to repay the financing, with sources including bond issuance and investment returns [7] - The company will closely monitor the progress of the share pledges and fulfill its disclosure obligations as required by laws and regulations [8] Group 3 - The company has scheduled its second extraordinary general meeting for December 2, 2025, with both onsite and online voting options available for shareholders [10][11] - The meeting will be held at Shanghai Tianxi Jiafu Puti Hotel, starting at 13:30 [12] - A detailed voting procedure is provided for A-share shareholders, including registration and voting methods [18][20]

Core Viewpoint - Fosun Pharma showcases its innovative products and global collaborations at the 8th China International Import Expo, highlighting its deep commitment to the global healthcare sector and continuous breakthroughs [1][3]. Group 1: Product Innovation and Localization - Fosun Pharma has successfully localized several innovative products, including the Da Vinci surgical robot and CAR-T cell therapy product Yikaida, benefiting numerous Chinese patients and enhancing industry standards [3]. - The Yikaida product has treated over 1,000 lymphoma patients since its debut at the first Import Expo in 2018, marking significant advancements in commercial insurance and clinical efficacy [3]. - The Da Vinci surgical robot has been installed over 460 times in mainland China and Hong Kong, serving more than 810,000 patients, with new systems showcased this year expanding its capabilities in minimally invasive surgery [3]. Group 2: Infrastructure and Investment - The launch of the Intuitive Medical headquarters in Shanghai, with an investment of approximately 700 million yuan, marks a significant shift for Fosun Pharma from exhibitor to investor, strengthening its local industrial foundation [4]. - The Magnetic Resonance Guided Focused Ultrasound system has been introduced to over ten key medical institutions in China, treating nearly 1,000 patients, with the new V2 model receiving CE and FDA certifications [4]. Group 3: Strategic Collaborations and Global Operations - Fosun Pharma's Marie® upright particle therapy system, recently FDA approved, represents a new approach to tumor treatment, significantly reducing construction and operational costs while accommodating various advanced therapies [6]. - A strategic partnership with Leo Cancer Care aims to accelerate the introduction of this technology in China, enhancing treatment accessibility for cancer patients [8]. - The company employs a dual strategy of "independent research and development + cooperative introduction," focusing on cutting-edge fields such as antibody therapy, ADC, and gene editing [8]. Group 4: International Expansion and Market Presence - Fosun Pharma's internationalization has progressed beyond trade, entering a new phase of "global operations," with over 1,000 overseas commercialization teams established in markets like the US, Europe, and Southeast Asia [8]. - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for 28.07% of total revenue, indicating strong international market penetration [8]. - The company's self-developed PD-1 inhibitor has been approved in nearly 40 countries, establishing a benchmark for "Chinese innovation going global" [8]. Group 5: Industry Impact and Future Outlook - Fosun Pharma's comprehensive global capabilities are reshaping the international competitiveness of Chinese pharmaceutical companies, serving as a model for industry innovation and integration in an era of global adjustment [9].

Core Viewpoint - Fosun Pharma (02196) announced that its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., has pledged and released part of its A-share holdings in the company, indicating ongoing financial maneuvers within the company [1] Group 1 - The controlling shareholder pledged 20 million shares of Fosun Pharma [1] - The controlling shareholder released 85.75 million shares from pledge [1]

Core Viewpoint - The China International Import Expo (CIIE) is significantly accelerating the speed at which innovative drugs enter the Chinese market, transforming the landscape for multinational pharmaceutical companies and benefiting countless patients [3][8]. Group 1: Innovative Drug Launches - A groundbreaking drug for delaying the progression of type 1 diabetes, Trelagliptin, made its Asian debut at the CIIE and received approval for market entry in September [10]. - Sanofi's innovative cardiovascular drugs and Gilead Sciences' long-acting HIV prevention drug, Lenacapavir, were showcased at the CIIE, indicating a trend of faster access to top-tier medications for Chinese patients [6][18]. - The "CIIE speed" is exemplified by Sanofi's drug Dupixent, which received approval in China ahead of the U.S. FDA, showcasing a record time for innovative drugs to benefit Chinese patients [11]. Group 2: Market Strategy and Investment - Multinational pharmaceutical companies are shifting from merely introducing products to deeper, full-industry chain strategies in China, with Sanofi establishing China as an independent strategic market unit [20][22]. - Novartis has conducted over 100 clinical trials in China and aims for 90% of new drug registrations to align with global timelines within the next two years [28]. - Gilead Sciences is focusing on synchronizing its research and development projects in China with global efforts, emphasizing the importance of the Chinese market [23][26]. Group 3: CIIE's Spillover Effect - The CIIE is not only expediting drug launches but also creating a "spillover effect" that enhances the overall healthcare landscape in China, allowing for broader access to innovative treatments [15][17]. - Since its inception, Novartis has had over 40 innovative drugs and indications approved in China, accounting for 40% of its total approvals in the country since 1987 [15]. - The CIIE serves as a high-level open platform that fosters consensus, innovation, and collaboration among pharmaceutical companies, ultimately changing the lives of Chinese patients [17].

Core Viewpoint - Fosun Pharma (600196)(02196) announced that its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., has completed the pledge and release of part of its A-share holdings, indicating active management of its equity position [1] Summary by Category - **Pledge and Release of Shares** - The company reported that 20 million shares were pledged and 85.75 million shares were released from pledge [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 1 月7 日 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年第二次臨時股東會會議資料》，僅供參閱。 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 1 月7 日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 召開2025 年第二次臨時股東會的通知》，僅供參閱。 承董事會命 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * ...